RU2000127751A - ANTI-TUMOR MEDICINE - Google Patents
ANTI-TUMOR MEDICINEInfo
- Publication number
- RU2000127751A RU2000127751A RU2000127751/14A RU2000127751A RU2000127751A RU 2000127751 A RU2000127751 A RU 2000127751A RU 2000127751/14 A RU2000127751/14 A RU 2000127751/14A RU 2000127751 A RU2000127751 A RU 2000127751A RU 2000127751 A RU2000127751 A RU 2000127751A
- Authority
- RU
- Russia
- Prior art keywords
- compound
- group
- platinum coordination
- antitumor agent
- stilbene derivative
- Prior art date
Links
- 230000000259 anti-tumor effect Effects 0.000 title claims 5
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 18
- 150000001875 compounds Chemical class 0.000 claims 17
- 239000002246 antineoplastic agent Substances 0.000 claims 10
- 229910052697 platinum Inorganic materials 0.000 claims 9
- PJANXHGTPQOBST-UHFFFAOYSA-N stilbene Chemical class C=1C=CC=CC=1C=CC1=CC=CC=C1 PJANXHGTPQOBST-UHFFFAOYSA-N 0.000 claims 9
- 125000003545 alkoxy group Chemical group 0.000 claims 6
- 230000001747 exhibiting effect Effects 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 3
- 125000004442 acylamino group Chemical group 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 125000004414 alkyl thio group Chemical group 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 2
- 229960004316 cisplatin Drugs 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 claims 2
- MQLACMBJVPINKE-UHFFFAOYSA-N 10-[(3-hydroxy-4-methoxyphenyl)methylidene]anthracen-9-one Chemical compound C1=C(O)C(OC)=CC=C1C=C1C2=CC=CC=C2C(=O)C2=CC=CC=C21 MQLACMBJVPINKE-UHFFFAOYSA-N 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- 125000005236 alkanoylamino group Chemical group 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 claims 1
- KLNFSAOEKUDMFA-UHFFFAOYSA-N azanide;2-hydroxyacetic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OCC(O)=O KLNFSAOEKUDMFA-UHFFFAOYSA-N 0.000 claims 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 claims 1
- 125000001589 carboacyl group Chemical group 0.000 claims 1
- 229960004562 carboplatin Drugs 0.000 claims 1
- PJANXHGTPQOBST-QXMHVHEDSA-N cis-stilbene Chemical group C=1C=CC=CC=1/C=C\C1=CC=CC=C1 PJANXHGTPQOBST-QXMHVHEDSA-N 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 229950007221 nedaplatin Drugs 0.000 claims 1
- 125000002560 nitrile group Chemical group 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- -1 phosphate ester Chemical class 0.000 claims 1
- PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
Claims (1)
причем, соединение может быть в форме соли, гидрата, сольвата или аналогичных формах; в которых R1, R2 и R3 независимы друг от друга, и каждый обозначает низший алкокси, R4, R5 и R6 независимы друг от друга, и каждый обозначает любую группу-заместитель из атома водорода, атома галогена, нитрогруппы, гидроксильной группы, низшего алкокси, эфира фосфорной кислоты, амида фосфорной кислоты, амино-низшей-алкоксигруппы, низшей алкиламино-низшей-алкоксигруппы, ди-низшей-алкиламино-низшей-алкоксигруппы, меркаптогруппы, низшей алкилтиогруппы, аминогруппы, низшей алкиламиногруппы, ди-низшей-алкиламиногруппы, низшей алкильной группы, амино-низшей-алкильной группы, трифторметильной группы, низшего алканоила, низшей алканоиламиногруппы и ациламиногруппы аминокислоты, Х обозначает атом водорода или нитрильную группу, и Het обозначает гетероциклическое кольцо.4. The antitumor agent according to claim 1, wherein said stilbene derivative is at least one of the compounds represented by the following general formulas (1) and (2)
moreover, the compound may be in the form of salt, hydrate, solvate, or similar forms; in which R 1 , R 2 and R 3 are independent of each other, and each denotes lower alkoxy, R 4 , R 5 and R 6 are independent of each other, and each denotes any substituent group from a hydrogen atom, a halogen atom, a nitro group, hydroxyl group, lower alkoxy, phosphate ester, phosphoric amide, amino-lower alkoxy, lower alkylamino-lower-alkoxy, di-lower-alkylamino-lower alkoxy, mercapto, lower alkylthio, amino, lower alkyloxy, mercapto, lower alkylthio, amine, alkyloxy -alkylamino, lower alkyl group, am a lower alkyl group, a trifluoromethyl group, a lower alkanoyl, a lower alkanoyl amino group and an acylamino group of an amino acid, X represents a hydrogen atom or a nitrile group, and Het represents a heterocyclic ring.
причем указанное соединение может быть в форме соли; и в которой R1, R2, R3 и R5 обозначают метоксигруппу, R4 обозначает любой один заместитель из аминогруппы и ациламиногруппы аминокислоты, а R6 и Х обозначают атом водорода.5. The antitumor agent according to claim 1, wherein said stilbene derivative is represented by the following general formula (1), and said platinum coordination compound is a compound exhibiting antitumor activity
moreover, the specified connection may be in the form of a salt; and in which R 1 , R 2 , R 3 and R 5 denote a methoxy group, R 4 denotes any one substituent from the amino group and the acylamino group of the amino acid, and R 6 and X denote a hydrogen atom.
7. Противоопухолевое средство по п. 1, в котором указанное координационное соединение платины представляет цисплатин, и указанное производное стильбена является соединением, представленным следующей структурной формулой (3)
8. Противоопухолевый агент, включающий производное стильбена или координационное соединение платины для противоопухолевого средства по п. 1, причем агент может необязательно содержать один или более фармацевтически приемлемых носителей, разбавителей и других веществ, необходимых для фармацевтического препарата.6. The antitumor agent according to claim 1, wherein said stilbene derivative is represented by the following structural formula (3), and said platinum coordination compound is a compound exhibiting antitumor activity
7. The antitumor agent according to claim 1, wherein said platinum coordination compound is cisplatin, and said stilbene derivative is a compound represented by the following structural formula (3)
8. An antitumor agent comprising a stilbene derivative or platinum coordination compound for an antitumor agent according to claim 1, wherein the agent may optionally contain one or more pharmaceutically acceptable carriers, diluents and other substances necessary for the pharmaceutical preparation.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP10870898 | 1998-04-03 | ||
| JP10/108708 | 1998-04-03 | ||
| JP10/229843 | 1998-08-14 | ||
| JP22984398 | 1998-08-14 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2000127751A true RU2000127751A (en) | 2002-09-20 |
| RU2215525C2 RU2215525C2 (en) | 2003-11-10 |
Family
ID=26448545
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2000127751/14A RU2215525C2 (en) | 1998-04-03 | 1999-03-29 | Antitumor agent |
Country Status (19)
| Country | Link |
|---|---|
| US (6) | US6462087B1 (en) |
| EP (1) | EP1068870B1 (en) |
| JP (3) | JP4470321B2 (en) |
| KR (1) | KR100598474B1 (en) |
| CN (1) | CN1140272C (en) |
| AT (1) | ATE328599T1 (en) |
| AU (1) | AU747599C (en) |
| BR (1) | BR9909393A (en) |
| CA (1) | CA2326761C (en) |
| DE (1) | DE69931766T2 (en) |
| DK (1) | DK1068870T3 (en) |
| ES (1) | ES2267255T3 (en) |
| HU (1) | HUP0102521A3 (en) |
| IL (1) | IL138723A (en) |
| NO (1) | NO328704B1 (en) |
| NZ (1) | NZ507221A (en) |
| PT (1) | PT1068870E (en) |
| RU (1) | RU2215525C2 (en) |
| WO (1) | WO1999051246A1 (en) |
Families Citing this family (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030158220A1 (en) * | 1997-11-03 | 2003-08-21 | Foss Joseph F. | Use of methylnaltrexone and related compounds to treat chronic opioid use side effects |
| RU2215525C2 (en) * | 1998-04-03 | 2003-11-10 | Адзиномото Ко., Инк. | Antitumor agent |
| US7037906B1 (en) * | 2000-12-22 | 2006-05-02 | Oxigene, Inc. | Methods for modulating tumor growth and metastasis |
| US20050209310A1 (en) * | 2000-12-22 | 2005-09-22 | Chaplin David J | Methods for modulating tumor growth and metastasis |
| CN101434517B (en) * | 2001-01-18 | 2014-08-27 | 北京文丰天济医药科技有限公司 | 1, 2-diphenylethylene derivatives for the treatment of immune disorders |
| US20020183266A1 (en) * | 2001-03-15 | 2002-12-05 | Aventis Pharma, S.A. | Combination comprising combretastatin and anticancer agents |
| CN101816794A (en) * | 2001-06-25 | 2010-09-01 | 味之素株式会社 | antineoplastic agent |
| KR20030018800A (en) * | 2001-08-31 | 2003-03-06 | 주식회사 프로메디텍 | Phenyl ring derivatives having cytochrome p450 1b1 inhibitory activity and pharmaceutically acceptable salts thereof, preparing process and compositions containing same |
| WO2004069243A1 (en) * | 2003-02-04 | 2004-08-19 | Kabushiki Kaisha Yakult Honsha | Breast cancer resistance protein (bcrp) inhibitor |
| DK2368553T3 (en) | 2003-04-08 | 2015-02-09 | Progenics Pharm Inc | Pharmaceutical preparation comprising methylnaltrexone |
| AU2006214164B2 (en) | 2005-02-17 | 2010-12-09 | Synta Pharmaceuticals Corp. | Isoxazole combretastin derivatives for the treatment of disorders |
| US8518962B2 (en) | 2005-03-07 | 2013-08-27 | The University Of Chicago | Use of opioid antagonists |
| US9662325B2 (en) | 2005-03-07 | 2017-05-30 | The University Of Chicago | Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
| WO2006096626A2 (en) * | 2005-03-07 | 2006-09-14 | The University Of Chicago | Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
| US8524731B2 (en) * | 2005-03-07 | 2013-09-03 | The University Of Chicago | Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
| AR057325A1 (en) * | 2005-05-25 | 2007-11-28 | Progenics Pharm Inc | SYNTHESIS OF (S) -N-METHYLNTREXONE, PHARMACEUTICAL COMPOSITIONS AND USES |
| AR057035A1 (en) | 2005-05-25 | 2007-11-14 | Progenics Pharm Inc | SYNTHESIS OF (R) -N-METHYLNTREXONE, PHARMACEUTICAL COMPOSITIONS AND USES |
| FR2895258B1 (en) * | 2005-12-22 | 2008-03-21 | Aventis Pharma Sa | COMBINATION COMPRISING COMBRETASTATIN AND ANTICANCER AGENTS |
| CN101085743B (en) * | 2006-06-06 | 2012-02-15 | 浙江大德药业集团有限公司 | Fluorine-containing alkoxy combretastatin derivative, preparation method and use thereof |
| TWI489984B (en) | 2006-08-04 | 2015-07-01 | Wyeth Corp | Formulations for parenteral delivery of compounds and uses thereof |
| TW200817048A (en) * | 2006-09-08 | 2008-04-16 | Wyeth Corp | Dry powder compound formulations and uses thereof |
| US8173686B2 (en) | 2006-11-06 | 2012-05-08 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
| US8168662B1 (en) | 2006-11-06 | 2012-05-01 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
| US8168661B2 (en) | 2006-11-06 | 2012-05-01 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
| US8178564B2 (en) | 2006-11-06 | 2012-05-15 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
| PE20130480A1 (en) | 2007-03-29 | 2013-05-08 | Progenics Pharm Inc | HETEROCYCLIC COMPOUNDS AS ANTAGONISTS OF THE PERIPHERAL OPIOID RECEPTOR |
| EP2134718A2 (en) | 2007-03-29 | 2009-12-23 | Progenics Pharmaceuticals, Inc. | Crystal forms of (r)-n-methylnaltrexone bromide and uses thereof |
| DK2565195T3 (en) | 2007-03-29 | 2015-06-29 | Wyeth Llc | PERIPHERAL OPIOID RECEPTOR AND ANTAGONISTS AND USES THEREOF |
| US8095816B1 (en) | 2007-04-05 | 2012-01-10 | Marvell International Ltd. | Processor management using a buffer |
| US8443187B1 (en) | 2007-04-12 | 2013-05-14 | Marvell International Ltd. | Authentication of computing devices in server based on mapping between port identifier and MAC address that allows actions-per-group instead of just actions-per-single device |
| US8321706B2 (en) | 2007-07-23 | 2012-11-27 | Marvell World Trade Ltd. | USB self-idling techniques |
| ES2529434T3 (en) | 2007-11-21 | 2015-02-20 | Oxigene, Inc. | Method to treat hematopoietic neoplasms |
| CN101959892B (en) | 2008-02-06 | 2014-01-08 | 普罗热尼奇制药公司 | Preparation and use of (R),(R)-2,2'-bis-methylnaltrexone |
| AU2009225434B2 (en) | 2008-03-21 | 2014-05-22 | The University Of Chicago | Treatment with opioid antagonists and mTOR inhibitors |
| CA2676881C (en) | 2008-09-30 | 2017-04-25 | Wyeth | Peripheral opioid receptor antagonists and uses thereof |
| RU2523339C2 (en) | 2008-11-14 | 2014-07-20 | Хистоджен, Инк. | Extracellular matrix compositions for treating cancer |
| FR2945210B1 (en) * | 2009-05-07 | 2011-07-01 | Sanofi Aventis | ANTITUMOR COMBINATION COMPRISING AVE8062 AND SORAFENIB |
| FR2953518B1 (en) | 2009-12-03 | 2012-01-20 | Sanofi Aventis | PROCESS FOR PREPARING A COMBRETASTATIN DERIVATIVE |
| EP2481404A1 (en) | 2010-11-15 | 2012-08-01 | Sanofi | An antitumoral combination comprising ombrabulin, a taxane derivative and a platinum derivative |
| EP2397135A1 (en) | 2010-06-18 | 2011-12-21 | Sanofi | An antitumoral combination comprising ombrabulin, a taxane derivative and a platinum derivative |
| CN103140224A (en) | 2010-06-18 | 2013-06-05 | 赛诺菲 | An antitumoral combination comprising ombrabulin, a taxane derivative and a platinum derivative |
| EP2407161A1 (en) | 2010-07-13 | 2012-01-18 | Sanofi | An antitumoral combination comprising ombrabulin and bevacizumab |
| FR2968557A1 (en) | 2010-12-09 | 2012-06-15 | Sanofi Aventis | ANTITUMOR COMBINATION COMPRISING A DRIFT OF THE COMBRETASTATIN FAMILY AND THE CETUXIMAB |
| CA2826034A1 (en) | 2011-01-28 | 2012-08-02 | University Of Kentucky Research Foundation | Stilbene analogs and methods of treating cancer |
| AU2012275841A1 (en) | 2011-06-27 | 2014-01-16 | The Jackson Laboratory | Methods and compositions for treatment of cancer and autoimmune disease |
| US9141394B2 (en) | 2011-07-29 | 2015-09-22 | Marvell World Trade Ltd. | Switching between processor cache and random-access memory |
| FR2978663A1 (en) | 2011-08-01 | 2013-02-08 | Sanofi Sa | ANTITUMOR COMBINATION COMPRISING OMBRABULIN AND CETUXIMAB ASSOCIATED WITH RADIOTHERAPY |
| FR2978662A1 (en) * | 2011-08-01 | 2013-02-08 | Sanofi Sa | ANTITUMOR COMBINATION COMPRISING OMBRABULIN AND CISPLATIN ASSOCIATED WITH RADIOTHERAPY |
| US9436629B2 (en) | 2011-11-15 | 2016-09-06 | Marvell World Trade Ltd. | Dynamic boot image streaming |
| WO2014089177A2 (en) | 2012-12-04 | 2014-06-12 | Massachusetts Institute Of Technology | Compounds, conjugates and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines |
| US9575768B1 (en) | 2013-01-08 | 2017-02-21 | Marvell International Ltd. | Loading boot code from multiple memories |
| WO2014144715A1 (en) | 2013-03-15 | 2014-09-18 | Memorial Sloan-Kettering Cancer Center | Hsp90-targeted cardiac imaging and therapy |
| US9458086B1 (en) | 2013-07-03 | 2016-10-04 | University Of South Florida (A Florida Non-Profit Corporation) | Compositions and methods for adipocyte modulation |
| WO2017031157A1 (en) | 2015-08-18 | 2017-02-23 | Mateon Therapeutics, Inc. | Use of vdas to enhance immunomodulating therapies against tumors |
| WO2017197045A1 (en) | 2016-05-11 | 2017-11-16 | Movassaghi Mohammad | Convergent and enantioselective total synthesis of communesin analogs |
| WO2018209239A1 (en) | 2017-05-11 | 2018-11-15 | Massachusetts Institute Of Technology | Potent agelastatin derivatives as modulators for cancer invasion and metastasis |
| CN107311846B (en) * | 2017-07-25 | 2022-05-13 | 上海华理生物医药股份有限公司 | Gem difluoroethyl substituted stilbene and diphenylethane derivatives, and preparation method and application thereof |
| US10640508B2 (en) | 2017-10-13 | 2020-05-05 | Massachusetts Institute Of Technology | Diazene directed modular synthesis of compounds with quaternary carbon centers |
| WO2020247054A1 (en) | 2019-06-05 | 2020-12-10 | Massachusetts Institute Of Technology | Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof |
| CN112225673B (en) * | 2020-11-13 | 2022-08-02 | 义乌市华耀医药科技有限公司 | Amino combretastatin derivative and application thereof |
| WO2022182415A1 (en) | 2021-02-24 | 2022-09-01 | Massachusetts Institute Of Technology | Himastatin derivatives, and processes of preparation thereof, and uses thereof |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH588505A5 (en) * | 1972-06-08 | 1977-06-15 | Research Corp | |
| JPS56103192A (en) * | 1980-01-18 | 1981-08-18 | Yoshinori Kitani | Novel platinum complex |
| US4935450A (en) * | 1982-09-17 | 1990-06-19 | Therapeutical Systems Corporation | Cancer therapy system for effecting oncolysis of malignant neoplasms |
| CA1338645C (en) * | 1987-01-06 | 1996-10-15 | George R. Pettit | Isolation, structural elucidation and synthesis of novel antineoplastic substances denominated "combretastatins" |
| CA1340994C (en) | 1989-09-21 | 2000-05-16 | Rudolf Edgar Dr. Falk | Treatment of conditions and disease |
| US5561136A (en) * | 1990-12-13 | 1996-10-01 | Merrell Pharmaceuticals Inc. | Method of treating cancer by conjunctive therapy with N,N'-bis[ethylamino)propyl]-1,7-heptanediamine and a cytotoxic agent |
| GB9106177D0 (en) * | 1991-03-22 | 1991-05-08 | Aston Molecules Ltd | Substituted diphenylethylenes and analogues or derivatives thereof |
| US5525622A (en) * | 1991-08-28 | 1996-06-11 | Bayer Aktiengesellschaft | Substituted pyrazolines |
| US5430062A (en) * | 1992-05-21 | 1995-07-04 | Research Corporation Technologies, Inc. | Stilbene derivatives as anticancer agents |
| FR2697752B1 (en) * | 1992-11-10 | 1995-04-14 | Rhone Poulenc Rorer Sa | Antitumor compositions containing taxane derivatives. |
| US5844001A (en) * | 1993-02-26 | 1998-12-01 | Research Development Foundation | Combination platinum chemotherapeutic/antiestrogen therapy for human cancers |
| US5409690A (en) * | 1993-06-23 | 1995-04-25 | Chemex Pharmaceuticals, Inc. | Treatment of multidrug resistant diseases in cancer cell by potentiating with masoprocol |
| TW325458B (en) * | 1993-09-08 | 1998-01-21 | Ajinomoto Kk | Stilbene derivatives and pharmaceutical compositions comprising the same for anti-cancer |
| US5731353A (en) * | 1993-09-08 | 1998-03-24 | Ajinomoto Co., Inc. | Stilbene derivatives and pharmaceutical compositions containing them |
| US6524832B1 (en) * | 1994-02-04 | 2003-02-25 | Arch Development Corporation | DNA damaging agents in combination with tyrosine kinase inhibitors |
| US5561122A (en) * | 1994-12-22 | 1996-10-01 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Combretastatin A-4 prodrug |
| TW334418B (en) * | 1995-03-07 | 1998-06-21 | Ajinomoto Kk | Stilbene derivatives and pharmaceutical compositions |
| JP3163391B2 (en) | 1995-03-07 | 2001-05-08 | 味の素株式会社 | Stilbene derivatives and anticancer agents containing the same |
| US5700826A (en) * | 1995-06-07 | 1997-12-23 | Ontogen Corporation | 1,2,4,5-tetra substituted imidazoles as modulators of multi-drug resistance |
| AU6906396A (en) * | 1995-08-30 | 1997-03-19 | Arch Development Corporation | Methods and compositions including dna damaging agents and tyrosine kinase inhibitors or activators |
| PL192633B1 (en) | 1997-02-05 | 2006-11-30 | Upjohn Co | Lipoid complexes and liposomes of highly insoluble platinum complexes |
| RU2215525C2 (en) * | 1998-04-03 | 2003-11-10 | Адзиномото Ко., Инк. | Antitumor agent |
| CZ292170B6 (en) | 1998-08-14 | 2003-08-13 | Pliva-Lachema A.S. | Carboplatin-based pharmaceutical composition exhibiting antineoplastic effect |
| GB9903403D0 (en) * | 1999-02-16 | 1999-04-07 | Angiogene Pharm Ltd | Substituted stilbene compounds with vascular damaging activity |
| GB9918912D0 (en) * | 1999-08-12 | 1999-10-13 | Angiogene Pharm Ltd | New stilbenes with vascular damaging activity |
| CA2432792C (en) * | 2000-12-22 | 2012-04-03 | Bristol-Myers Squibb Company | Methods for modulating tumor growth and metastasis |
| US20020183266A1 (en) * | 2001-03-15 | 2002-12-05 | Aventis Pharma, S.A. | Combination comprising combretastatin and anticancer agents |
| CN101816794A (en) * | 2001-06-25 | 2010-09-01 | 味之素株式会社 | antineoplastic agent |
-
1999
- 1999-03-29 RU RU2000127751/14A patent/RU2215525C2/en not_active IP Right Cessation
- 1999-03-29 IL IL13872399A patent/IL138723A/en not_active IP Right Cessation
- 1999-03-29 CA CA002326761A patent/CA2326761C/en not_active Expired - Fee Related
- 1999-03-29 AU AU29607/99A patent/AU747599C/en not_active Ceased
- 1999-03-29 DK DK99910779T patent/DK1068870T3/en active
- 1999-03-29 AT AT99910779T patent/ATE328599T1/en active
- 1999-03-29 HU HU0102521A patent/HUP0102521A3/en unknown
- 1999-03-29 PT PT99910779T patent/PT1068870E/en unknown
- 1999-03-29 JP JP2000542017A patent/JP4470321B2/en not_active Expired - Fee Related
- 1999-03-29 NZ NZ507221A patent/NZ507221A/en not_active IP Right Cessation
- 1999-03-29 ES ES99910779T patent/ES2267255T3/en not_active Expired - Lifetime
- 1999-03-29 CN CNB998067555A patent/CN1140272C/en not_active Expired - Fee Related
- 1999-03-29 WO PCT/JP1999/001633 patent/WO1999051246A1/en active IP Right Grant
- 1999-03-29 DE DE69931766T patent/DE69931766T2/en not_active Expired - Lifetime
- 1999-03-29 BR BR9909393-6A patent/BR9909393A/en not_active Application Discontinuation
- 1999-03-29 EP EP99910779A patent/EP1068870B1/en not_active Expired - Lifetime
- 1999-03-29 KR KR1020007010971A patent/KR100598474B1/en not_active Expired - Fee Related
-
2000
- 2000-09-29 NO NO20004911A patent/NO328704B1/en not_active IP Right Cessation
- 2000-10-03 US US09/678,406 patent/US6462087B1/en not_active Expired - Lifetime
-
2002
- 2002-05-29 US US10/156,105 patent/US20020193434A1/en not_active Abandoned
- 2002-06-12 US US10/166,763 patent/US6992106B2/en not_active Expired - Fee Related
-
2005
- 2005-08-04 US US11/196,454 patent/US7655696B2/en not_active Expired - Fee Related
-
2008
- 2008-12-15 US US12/334,846 patent/US7973076B2/en not_active Expired - Fee Related
-
2009
- 2009-08-24 JP JP2009192918A patent/JP5056816B2/en not_active Expired - Fee Related
- 2009-11-20 US US12/622,508 patent/US20100069486A1/en not_active Abandoned
- 2009-12-10 JP JP2009280444A patent/JP5120368B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2000127751A (en) | ANTI-TUMOR MEDICINE | |
| RU2215525C2 (en) | Antitumor agent | |
| RU2350605C2 (en) | Analogues of quinazoline as inhibitors of receptor tyrosine kinases | |
| RU2000125568A (en) | DERIVATIVES OF CYCLOALKENES, THEIR RECEPTION AND APPLICATION | |
| RU2019133646A (en) | Isoquinolines as HPK1 Inhibitors | |
| RU2005140570A (en) | PHARMACEUTICAL COMPOSITION CONTAINING A HISTONDEACETYLASE INHIBITOR | |
| RU92004336A (en) | WATER-SOLUBLE DERIVATIVES OF CAMPTOTECINE, METHOD FOR THEIR PRODUCTION, PHARMACEUTICAL COMPOSITION, METHOD FOR INHIBITING ENZYM TOOPOISOMERS, INTERMEDIATE PRODUCTS | |
| RU2003122190A (en) | TETRAHYDROPYRIDINE DERIVATIVES, THEIR PRODUCTION AND APPLICATION AS CELL PROLIFERATION INHIBITORS | |
| RU2004106617A (en) | ANTITUMOR ANALOGUES | |
| RU2015107803A (en) | DIHYDROXYPYrimidinecarboxylic Acid Derivatives AND THEIR APPLICATION IN TREATMENT, TREATMENT OR PREVENTION OF VIRAL DISEASE | |
| RU2008119692A (en) | NEW 1-AZABicycloalkyl derivatives for the treatment of mental disorders | |
| NZ515282A (en) | Substituted phenyl compounds with immunosuppressing activity and pharmaceutical compositions | |
| RU93004675A (en) | 1,2,4-Oxadiazolyl-phenoxyalkylisoxazoles, their use as antiviral agents, pharmaceutical composition | |
| KR910007883A (en) | Quinoline derivatives, preparation method and use thereof | |
| DE3681359D1 (en) | 6-PHENYL-PYRIDAZINE COMPOUNDS. | |
| RU2003130644A (en) | RARCARBOLINE DERIVATIVES AND THEIR PHARMACEUTICAL USE AGAINST DIPRESSION AND FEAR | |
| RU2006146204A (en) | 3-D-Ribofuranosylthiazole [4, 5-D] Pyrimidine Nucleosides and Their Applications | |
| KR940009184A (en) | Pyrazole condensed ring derivatives, preparation method thereof and androgen inhibitor | |
| RU2004111787A (en) | RETINOID AGONISTS (1), ALKYL UREA DERIVATIVES | |
| RU2002105374A (en) | COMBINED THERAPY USING PENTAFLUORBENZENESULPHANAMIDES | |
| RU94011565A (en) | THIOXANTENONE COMPOUNDS, THEIR USE, ANTI-SMALL COMPOSITION | |
| RU2008149461A (en) | Phosphorus-containing compounds, including the complex esters of triphenylmethylphosphonic acid for the treatment of melanoma and other cancerous diseases | |
| CA2453991A1 (en) | New antitumoral derivatives of et-743 | |
| RU2003103856A (en) | VARIOLIN DERIVATIVES, METHODS FOR THEIR PRODUCTION AND APPLICATION OF THE INDICATED SUBSTANCES AS ANTI-CANCER AGENTS | |
| CA2575512A1 (en) | Quinazoline derivatives useful for the treatment of peripheral arterial disease and as phosphodiesterase inhibitors |